What GPs need to know about TNF-a inhibitors
Psoriasis is a chronic skin disorder that affects around 2% of the population in the UK. Approximately 20% of patients have moderate-to-severe disease requiring either systemic therapy or phototherapy. The use of these traditional systemic therapies is limited by their side-effects, particularly organ toxicity. Advances in the understanding of the pathogenesis of a number of inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis, have led to the development of more precisely targeted biological therapies.
Dermatology in practice 2005; 13(2): 22–24
To continue reading this article, please sign in or register.